Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.

Abstract:

:Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clinical trials, aliskiren and HCTZ (as a combination of the individual components or as single-pill combinations) reduced mean sitting systolic and diastolic BP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and HCTZ monotherapy. Aliskiren/HCTZ produced additional BP reductions in patients inadequately responsive to 4 weeks' prior treatment with aliskiren or HCTZ alone. Responder rates and BP control rates further demonstrated the benefits of aliskiren/HCTZ combination therapy over monotherapy with individual components in patients with mild to moderate hypertension. Aliskiren plus HCTZ appeared to be effective as long-term (up to 1 year) combination treatment in an open-label trial. In a 12-week placebo-controlled trial in obese patients with hypertension, BP reductions and responder and control rates were significantly greater with aliskiren/HCTZ than with HCTZ alone. Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature.

journal_name

Drugs

journal_title

Drugs

authors

Baldwin CM,Plosker GL

doi

10.2165/00003495-200969070-00004

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

833-41

issue

7

eissn

0012-6667

issn

1179-1950

pii

4

journal_volume

69

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.

    abstract::The meningococcal groups C and Y and Haemophilus b (Hib) tetanus toxoid conjugate vaccine (HibMenCY-TT) contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens, and Hib capsular polysaccharide [polyribosyl-ribitol-phosphate (PRP)]. The HibMenCY-TT vaccine is available in the USA for use as a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0048-9

    authors: Perry CM

    更新日期:2013-05-01 00:00:00

  • Low molecular weight heparins: a guide to their optimum use in pregnancy.

    abstract::The incidence of pulmonary embolism (PE) and venous thromboembolism (VTE) is higher in pregnant patients than in non-pregnant patients. The incidence of thrombosis in all pregnancies is reported to be between 0.05 and 1%, and an incidence as high as 3% may be present in women after caesarean section. Anticoagulant med...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262030-00004

    authors: Laurent P,Dussarat GV,Bonal J,Jego C,Talard P,Bouchiat C,Cellarier G

    更新日期:2002-01-01 00:00:00

  • Use of beta-adrenoreceptor blockers in combination with beta-stimulators in patients with obstructive lung disease.

    abstract::Lung function can be reduced not only by a non-selective beta-blocker but also by a selective beta1-receptor blocker. If both types of drug are without intrinsic sympathomimetic activity, the effect of the non-selective drug is more pronounced than that of a beta1-receptor selective drug under basal conditions. The ef...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197600111-00035

    authors: Johnsson G

    更新日期:1976-01-01 00:00:00

  • Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

    abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753050-00012

    authors: Bryson HM,Faulds D

    更新日期:1997-05-01 00:00:00

  • A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.

    abstract:BACKGROUND:Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE:This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnanc...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40265-017-0762-9

    authors: Kelty E,Hulse G

    更新日期:2017-07-01 00:00:00

  • Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study.

    abstract::The effect of cefotaxime and ceftriaxone on faecal flora was investigated in women undergoing routine vaginal or abdominal hysterectomy. Three groups of 9 patients received, in a double-blind fashion and just before surgery, cefotaxime 2g intravenously, ceftriaxone 2g intravenously or no antibiotic (controls). Stools ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800352-00004

    authors: Michéa-Hamzehpour M,Auckenthaler R,Kunz J,Pechère JC

    更新日期:1988-01-01 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.

    abstract::Available data indicate that the most common beta-lactamase produced by Branhamella catarrhalis is plasmid mediated. The same enzyme occurs in Moraxella nonliquefaciens, a commensal in the upper respiratory tract. The ability to produce the enzyme, which is known as BRO-1, can be transferred by conjugation from M. non...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600313-00026

    authors: Eliasson I,Kamme C

    更新日期:1986-01-01 00:00:00

  • Olaratumab: First Global Approval.

    abstract::Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0680-2

    authors: Shirley M

    更新日期:2017-01-01 00:00:00

  • [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

    abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856002-00004

    authors: Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

    更新日期:1998-01-01 00:00:00

  • Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

    abstract::Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587570-000000000-00000

    authors: Reginster JY

    更新日期:2011-01-01 00:00:00

  • Panobinostat: first global approval.

    abstract::Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0388-8

    authors: Garnock-Jones KP

    更新日期:2015-04-01 00:00:00

  • Letermovir: First Global Approval.

    abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0860-8

    authors: Kim ES

    更新日期:2018-01-01 00:00:00

  • Spread the Word: There Are Two Opioid Crises!

    abstract::Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01342-8

    authors: Marchetti Calônego MA,Sikandar S,Ferris FD,Moreira de Barros GA

    更新日期:2020-08-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Enasidenib: First Global Approval.

    abstract::Enasidenib (Idhifa®) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0813-2

    authors: Kim ES

    更新日期:2017-10-01 00:00:00

  • Retention in care and medication adherence: current challenges to antiretroviral therapy success.

    abstract::Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-015-0373-2

    authors: Holtzman CW,Brady KA,Yehia BR

    更新日期:2015-04-01 00:00:00

  • Early intervention in multiple sclerosis : better outcomes for patients and society?

    abstract::Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363150-00001

    authors: Flachenecker P,Rieckmann P

    更新日期:2003-01-01 00:00:00

  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

    abstract::Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly imp...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363210-00001

    authors: Bradford DW,Perkins DO,Lieberman JA

    更新日期:2003-01-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

    abstract::The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447020-00003

    authors: Luqmani R,Gordon C,Bacon P

    更新日期:1994-02-01 00:00:00

  • Steroid-refractory severe ulcerative colitis: what are the available treatment options?

    abstract::Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868090-00001

    authors: Moss AC,Peppercorn MA

    更新日期:2008-01-01 00:00:00

  • Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.

    abstract::A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700341-00017

    authors: Grassi C,Gialdroni Grassi G,Mangiarotti P

    更新日期:1987-01-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161030-00008

    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

    abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363220-00015

    authors: Cheer SM,Waugh J,Noble S

    更新日期:2003-01-01 00:00:00

  • Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents.

    abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00011

    authors: McCormack PL,Plosker GL

    更新日期:2006-01-01 00:00:00

  • Overview of the management of acute gout and the role of adrenocorticotropic hormone.

    abstract::It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on wh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868040-00002

    authors: Schlesinger N

    更新日期:2008-01-01 00:00:00